MX2019013769A - Derivados de resiquimod. - Google Patents
Derivados de resiquimod.Info
- Publication number
- MX2019013769A MX2019013769A MX2019013769A MX2019013769A MX2019013769A MX 2019013769 A MX2019013769 A MX 2019013769A MX 2019013769 A MX2019013769 A MX 2019013769A MX 2019013769 A MX2019013769 A MX 2019013769A MX 2019013769 A MX2019013769 A MX 2019013769A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- disclosed
- methods
- resiquimod
- derivatives
- Prior art date
Links
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical class C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto deuterado que tiene la fórmula estructural I o una sal farmacéuticamente aceptable del mismo: (Ver Formula I) Los valores y valores de ejemplo de la variable en la fórmula (I) se divulgan en el presente documento. También se divulga el uso de compuestos de fórmula (I) en los métodos para tratar una enfermedad seleccionada de cáncer, una enfermedad autoinmune, y una enfermedad infecciosa, y métodos para mejorar la respuesta inmunológica a un antígeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508722P | 2017-05-19 | 2017-05-19 | |
| PCT/US2018/033493 WO2018213769A1 (en) | 2017-05-19 | 2018-05-18 | Derivatives of resiquimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013769A true MX2019013769A (es) | 2020-07-20 |
Family
ID=62528901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013769A MX2019013769A (es) | 2017-05-19 | 2018-05-18 | Derivados de resiquimod. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11274099B2 (es) |
| EP (1) | EP3625231B1 (es) |
| JP (1) | JP7228574B2 (es) |
| KR (1) | KR102650538B1 (es) |
| CN (2) | CN116854686A (es) |
| AU (1) | AU2018270266B2 (es) |
| BR (1) | BR112019024177A2 (es) |
| CA (1) | CA3063953A1 (es) |
| DK (1) | DK3625231T3 (es) |
| ES (1) | ES2928723T3 (es) |
| IL (1) | IL270703B2 (es) |
| MX (1) | MX2019013769A (es) |
| PH (1) | PH12019502544A1 (es) |
| WO (1) | WO2018213769A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3625231B1 (en) | 2017-05-19 | 2022-07-20 | Superb Wisdom Limited | Derivatives of resiquimod |
| CN118317772A (zh) * | 2021-09-17 | 2024-07-09 | 博笛生物科技有限公司 | 氘化咪唑并喹啉的组合疗法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| WO1992015582A1 (en) * | 1991-03-01 | 1992-09-17 | Minnesota Mining And Manufacturing Company | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| KR100235389B1 (ko) * | 1991-03-01 | 1999-12-15 | 스프레이그 로버트 월터 | 1-치환된, 2-치환된 1H-이미다조[4,5-c]퀴놀린-4-아민 |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| HUP9904665A3 (en) | 1996-10-25 | 2000-11-28 | Minnesota Mining And Mfg Co Sa | Immune response modifier compounds for treatment of th2 mediated and related diseases |
| BR0007435A (pt) | 1999-01-08 | 2001-12-04 | 3M Innovative Properties Co | Formulações e métodos para tratamento decondições associadas com mucosa com ummodificador de resposta imunológica |
| US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| ATE282428T1 (de) | 2001-05-03 | 2004-12-15 | Hoffmann La Roche | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US20060183767A1 (en) | 2003-01-06 | 2006-08-17 | Eugene Mandrea | Methods of stimulating immune response in certain individuals |
| EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| CN101076319A (zh) | 2004-09-29 | 2007-11-21 | 科迪斯公司 | 稳定的非晶形雷帕霉素样化合物的药物剂型 |
| JP2016515538A (ja) * | 2013-03-15 | 2016-05-30 | ブレット バイオテクノロジー、 インク．Ｂｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 特異的な多価ウイルス様粒子ワクチンおよびその使用 |
| EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| WO2017079431A1 (en) * | 2015-11-05 | 2017-05-11 | The General Hospital Corporation | Methods for treating cancer by enhancing intratumoral immune response |
| EP3625231B1 (en) | 2017-05-19 | 2022-07-20 | Superb Wisdom Limited | Derivatives of resiquimod |
-
2018
- 2018-05-18 EP EP18729301.4A patent/EP3625231B1/en active Active
- 2018-05-18 MX MX2019013769A patent/MX2019013769A/es unknown
- 2018-05-18 BR BR112019024177-9A patent/BR112019024177A2/pt unknown
- 2018-05-18 ES ES18729301T patent/ES2928723T3/es active Active
- 2018-05-18 CN CN202310632172.XA patent/CN116854686A/zh active Pending
- 2018-05-18 KR KR1020197037270A patent/KR102650538B1/ko active IP Right Grant
- 2018-05-18 CA CA3063953A patent/CA3063953A1/en active Pending
- 2018-05-18 CN CN201880044288.9A patent/CN111094282B/zh active Active
- 2018-05-18 WO PCT/US2018/033493 patent/WO2018213769A1/en unknown
- 2018-05-18 DK DK18729301.4T patent/DK3625231T3/da active
- 2018-05-18 US US16/612,216 patent/US11274099B2/en active Active
- 2018-05-18 JP JP2020514152A patent/JP7228574B2/ja active Active
- 2018-05-18 AU AU2018270266A patent/AU2018270266B2/en active Active
-
2019
- 2019-11-14 PH PH12019502544A patent/PH12019502544A1/en unknown
- 2019-11-17 IL IL270703A patent/IL270703B2/en unknown
-
2022
- 2022-02-04 US US17/665,104 patent/US20230002370A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111094282A (zh) | 2020-05-01 |
| DK3625231T3 (da) | 2022-10-31 |
| CN111094282B (zh) | 2023-06-16 |
| RU2019141473A3 (es) | 2021-09-17 |
| US20230002370A1 (en) | 2023-01-05 |
| CN116854686A (zh) | 2023-10-10 |
| EP3625231A1 (en) | 2020-03-25 |
| ES2928723T3 (es) | 2022-11-22 |
| AU2018270266A1 (en) | 2020-01-16 |
| BR112019024177A2 (pt) | 2020-06-02 |
| IL270703B1 (en) | 2023-03-01 |
| KR102650538B1 (ko) | 2024-03-21 |
| KR20200038889A (ko) | 2020-04-14 |
| JP2020520993A (ja) | 2020-07-16 |
| EP3625231B1 (en) | 2022-07-20 |
| WO2018213769A1 (en) | 2018-11-22 |
| US20200207757A1 (en) | 2020-07-02 |
| IL270703B2 (en) | 2023-07-01 |
| IL270703A (en) | 2020-01-30 |
| US11274099B2 (en) | 2022-03-15 |
| JP7228574B2 (ja) | 2023-02-24 |
| PH12019502544A1 (en) | 2020-07-13 |
| CA3063953A1 (en) | 2018-11-22 |
| AU2018270266B2 (en) | 2022-06-30 |
| RU2019141473A (ru) | 2021-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501688A1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
| MX2019012233A (es) | Anticuerpos anti-sirpa. | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| WO2017030823A3 (en) | Anti-tigit antibodies | |
| MX2022007522A (es) | Anticuerpos anti-cd27. | |
| PH12019500480A1 (en) | Pyridine compound | |
| MX2022013524A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| MX2019007156A (es) | Inhibidores de imidazopirazina de la tirosina cinasa de bruton. | |
| MY196749A (en) | Eif4a-inhibiting compounds and methods related thereto | |
| GEP20207126B (en) | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| WO2017214170A3 (en) | Baff-r antibodies and uses thereof | |
| PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
| CY1121334T1 (el) | Αναστολεας κινασης aurora a | |
| SG10201903621SA (en) | Tricyclic atropisomer compounds | |
| PH12019502544A1 (en) | Derivatives of resiquimod | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| MY180727A (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease |